Fifty years chlorpromazine: A historical perspective

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 4, 2007, Pages 495-500

  Ban, Thomas A ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE   (Canada)

Author keywords

Chlorpromazine; History; Neuropsychopharmacology; Pharmacotherapy; Psychiatry; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; BARBITURIC ACID DERIVATIVE; CHLORPROMAZINE; DOPAMINE; HALOPERIDOL; LYSERGIDE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; PHENOTHIAZINE DERIVATIVE; SEDATIVE AGENT; SEROTONIN; SUBSTANCE P;

DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SUBSTITUTION; DRUG SYNTHESIS; ELECTRIC SHOCK; FEEDBACK SYSTEM; HUMAN; NONHUMAN; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SPECTROFLUOROMETRY; VEIN DISEASE;

EID: 35649016151     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Anton-Stephens D. 1954. Preliminary observations on the psychiatric uses of chlorpromazine (Largactil). Journal of Mental Science, 100:543-57.
2. Arnold OH, Hilt S, Solma W. 1952. Über die Anwendung eines vegatativen Hemmungs stoffes in der psychiatrischen Therapie. Wiener Medinische Wochenschrift, 102:965-9.
3. Ayd FJ. 1959. A clinical analysis of the differential effects of phenothiazine derivatives. In Bradley PB, Deniker P, Radouco-Thomas C (eds). Neuropsychopharmacology. Amsterdam: Elsevier. pp 487-8.
4. Ban TA. 1969. Psychopharmacology. Baltimore: Williams & Wilkins. p 431.
5. Ban TA. 1972. Schizophrenia: A Psychopharmacological Approach. Springfield: Charles C. Thomas. pp 68-70.
6. Ban TA. 1987. Prolegomenon to the clinical prerequisite. Psychopharmacology and the classification of mental disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 11:527-80.
7. Ban TA. 1990.Clinical pharmacology and Leonhard's classification of endogenous psychoses. Psychopathology, 23:331-8.
8. Ban TA. 1994. Nobel Prize and Albert Lasker Award. In Ban TA, Hippius H (eds.). Towards CINP. Brentwood: JM Productions. pp 8-14.
9. Ban TA. 1999. Selective drugs versus heterogeneous diagnoses: towards a new methodology in psychopharmacological research. Psiquiatria Biologica, 7:177-89.
10. Ban TA. 2001. Pharmacotherapy of mental illness. A historical analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25:709-27.
11. Ban TA. 2004. Neuropsychopharmacology and the history of pharmacotherapy in psychiatry. A review of developments in the 20th century. In Ban TA, Healy D, Shorter E (eds.). Reflections on Twentieth-Century Psychopharmacology. Budapest: Animula. pp 697-720.
12. Ban TA, Guy W, Wilson WH. 1986. Research methodology and the pharmacology of the chronic schizophrenias. Psychopharmacology Bulletin, 22:36-41.
13. Ban TA, Healy D, Shorter E. 1998. Preface. In Ban TA, Healy D, Shorter E (eds). The rise of psychhopharmacology and the story of CINP. Budapest: Animula. pp VII-VIII.
14. Bente D, Itil TM. 1954. Zur Wirkung des Phenothiazin Körpers Megaphen auf das menschliche Hirnströmbild. Arzneimeittel Forschung, 4:418-23.
15. Bowman RL, Caulfield PA, Udenfriend S. 1955. Spectrophotometric assay in the visible and ultraviolet. Science, 122:32-3.
16. Burger A. 1976. History. In Usdin E, Forrest IS (eds). Psychotherapeutic Drugs. Part I Principles. New York and Basel: Marcel Dekker. pp 11-57.
17. Caldwell AE. 1970. Origins of Psychopharmacology From CPZ to LSD. Springfield: Charles C. Thomas. pp 23-35.
18. Carlsson A. 1998. Neuropsychopharmacology. In Ban TA, Healy D, Shorter E (eds). The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula. pp 124-8.
19. Carlsson A. 2004. The discovery of chlorpromazine - Impact on basic research. The International Journal of Neuropsychapharmacology, 7 (supplement 1):22.
20. Carlsson A, Lindqvist M. 1963. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacologica et Toxicologica, 20:140-4.
21. Charpentier P, Gailliot P, Jacob R, et al. 1952. Recherches sur les diméthylaminopropyl-N phénothiazines substituées. Comptes rendus de l'Académie des sciences (Paris), 235:59-60.
22. Cook L. 2004a. Reflections on the introduction of chlorpromazine in the United States. In Ban TA, Healy D, Shorter E (eds). Reflections on Twentieth-Century Psychopharmacology. Budapest: Animula. pp 178-81.
23. Cook L. 2004b. Early pharmacology of chlorpromazine. The International Journal of Neuropsychopharmacology, 7 (supplement 1):21.
24. Courvoisier S, Fournel J, Ducrot R, et al. 1953. Propriétés pharmacodynamiques du chlorhydrate de chloro-3-(diméthylamino-3′-propyl)-10-phénothazine (4560 RP). Étude expérimentale d'un niveau corps utilisé dans l'anesthésie potentialisée et dans l'hibernation artificielle. Archives internationales de pharmacodymnamie et de thérapie, 92:305-361.
25. 3H-halo-peridol. Life Science, 17:993-1001.
26. Delay J, Deniker P. 1952a. Le traitments de psychoses par une méthode neurolytique dérivée de l'hibernothérapie; le 4560 RP utilisée seul en cure prolongée et continue. CR Congr Méd Alién Neurol (France), 50:497-502.
27. Delay J, Deniker P. 1952b. 38 cas de psychoses traitèes par la cure prolongée et continuè de4560 RP. CR Congr Méd Alién Neurol (France), 50:503-13.
28. Delay J, Deniker P. 1952c. Réactions biologiques observées au cours du traitement par l'chlorhydrate de deméthylaminopropyl-N-chlorophénothiazine. CR Congr Méd Alién Neurol (France), 50:514-8.
29. Delay J, Deniker P, Harl JM. 1952a. Utilisation en thérapeutique d'une phénothiazine d'action centrale selective. Annales Médico-psychologiques, 110:112-7.
30. Delay J, Deniker P, Harl JM. 1952b. Traitement des ètats d'excitation et d'agitation par une méthode médicamenteuse dérivè de l'hibernothèrapie. Annales Médico-psychologiques, 110:267-73.
31. Delay J, Deniker P, Harl JM, et al. 1952c. Traitements d'ètats confusionnels par l'chlorhydrate de diméthylaminopropyl - N - chlorophénothiazine (4560 RP). Annales Médico-psychologiques, 110:112-7.
32. Elkes J, Elkes Ch. 1954. Effects of chlorpromazine on the behavior of chronically overactive psychotic patients. British Medical Journal, 2:560-76.
33. Fish FJ 1964. The influence of the tranquilizers on the Leonhard schizophrenic syndromes. Encephale, 53:245-9.
34. Follin S. 1952. Discussion. Annales Médico-psychologiques, 110:126-7.
35. Freyhan F. 1961. The influence of specific and non-specific factors on the clinical effects of psychotropic drugs. In Rothlin E (ed). Neuropsychopharmacology 2. Amsterdam: Elsevier. pp 183-8.
36. Griesinger W. 1845. Die pathologie und therapie des psychischen krankheiten. Wreden: Braunschweig.
37. Gyermek L. 1955. Chlorpromazine: A serotonin antagonist? The Lancet 2:724.
38. Gyermek L, Lázár GT, Csák Zs. 1956. The antiserotonin action of chlorpromazine and some other phenothiazine derivatives. Arch Int Pharmacodyn, 107:62-74.
39. Hamon J, Paraire J, Velluz J. 1952. Remarques sur l'action du 4560 RP sur l'agitation maniaque. Annales Médico-psychologiques (Paris). 110:331-5.
40. Hippius H. 2004. From chlorpromazine to modern ("atypical") antipsychotics. The International Journal of Neuropsychopharmacology, 7 (supplement 1):21-2.
41. Hippius H, Selbach H. 1959. On the correlation of the pharmacologically effective qualities of a drug to its therapeutic effect in psychoses. In Bradley PB, Deniker P, Radouco-Thomas C (eds). Neuropsychopharmacology (pp.598-601). Amsterdam: Elsevier. pp 598-601.
42. Hollister LE. 1994. Review of International Colloquium on Chlorpromazine. In: Ban TA, Hippius H (eds). Towards CINP. Brentwood: JM Productions.pp 18-23.
43. Janssen PAJ. 1998. Function and dysfunction of the basal ganglia. In Ban TA, Healy D, Shorter E (eds). The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula. pp 63-8.
44. Kardos G, Pertorini R. 1955. Largactil a psychiátriában. Ideggyogyászati Szemle, 8:65-9.
45. Laborit H, Huguenard P, Alluaume R. 1952. Un noveau stabilisateur végétatif (le 4560 RP). La Presse Médicale, 60:206-8.
46. Lambert P. 1998. Chlorpromazine: A true story of the progress affected by this drug. In: Ban TA, Healy D, Shorter E. (eds). The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula. pp 237-43.
47. Lambert P, Perrin J, Revol L, et al. 1959. Essai de classification des neuroleptiques d'après leurs activités psycho-pharmacologiques et cliniques. In Bradley PB, Deniker P, Radouco-Thomas C (eds). Neuropsychopharmacology. Amsterdam: Elsevier. pp 619-24.
48. Lehmann HE. 1954. Selective inhibition of affective drive by pharmacological means. American Journal of Psychiatry, 110:856-7.
49. Lehmann HE, Hanrahan GE. 1954. Chlorpromazine, new inhibiting agent for psychomotor exctietemnt and manic states. Archives of Neurology and Psychiatry (Chicago), 71:227-37.
50. Leonhard K. 1957. Aufteilung der endogenen Psychosen Berlin: Academie Verlag. pp 155-396.
51. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in chronic schizophrenia. New England Journal of Medicine, 353:1209-13.
52. Macht DL. 1920. Contributions to psychopharmacology. Johns Hopkins Hospital. Bulletin, 31:167-73.
53. Moreau de Tours J. 1845. Du Hachich et de L'Alienation Mentale. Etude Psychologiques. Paris: Fortin & Mason.
54. Olie JP. 2004. The discovery of chlorpromazine: A historical account. The International Joirnal of Neuropsychopharmacology, 7(suppl 1):21.
55. Rigorti S. 1952. Del blocco del SN vegetativo all'ibernazione artificiale primi risultati di un nuevo indirizzo di terapia psichiatrica. Rassegna di neurologia vegetative, 9:197-210.
56. Sal y Rosas F, Jeri R, Sanchez J. 1954. Chlorpromzine in neuropsychiatry Journal of the American Medical Association, 156:558.
57. Seeman P, Chau-Wong M, Tedesco J, Wong K. 1975. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proceedings of the National Academy of Sciences (USA), 72:4376-80.
58. Staehelin JE. 1954. Einige allgemeine Bemerkungen uber die Largactiltherapie in der psychiatrischen Universitatsklinik Basel. Schweizerische Archives für Neurologie und Psychiatrie, 73:288-91.
59. Staehelin JE, Kielholz P. 1953. Largactil, ein neues vegatativen Dämpfungsmittel bei psychischen Störungen. Schweizerische Medizinische Wochenschrift, 83:581-6.
60. Tarasov GK. 1955. Aminazine, review of the literature on the psychiatric use of a phenothiazine derivative. Zhurnal Nevropatologii i Psikhiatria Korsakov, 55:296-310.
61. Thuillier J. 1999. Ten Years That Changed the Face of Mental Illness London: Martin Dunitz. PP 111-23.
62. Webb RR. 1955. Largactil mpsychiatry. The Medical Journal of Australia 1:759-61.
63. Winkelman NW, 1954. Chlorpromazine in the treatment of neuropsychiatric disorders. Journal of the American Medical Association, 155:18-21.
64. Winter CA, Flataker L. 1951. The effect of antihistaminic drugs upon the performance of trained rats. Journal of Pharmacology and Experimental Therapeutics, 101:156-62.
65. Woolley DW, Shaw E. 1954. A biochemical and pharmacological suggestion about certain mental disorders. Proceedings of the National Academy of Sciences (USA), 40:228-31